Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 8/20 | 0.59 |
| ▸ | NPC1 | O15118 | 6/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.59 |
| ▸ | AGTR1 | P30556 | 2/20 | 0.59 |
| ▸ | HPGD | P15428 | 1/20 | 0.59 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.55 |
| ▸ | CA12 | O43570 | 2/20 | 0.48 |
| ▸ | CA1 | P00915 | 2/20 | 0.48 |
| ▸ | CA2 | P00918 | 2/20 | 0.48 |
| ▸ | CA9 | Q16790 | 2/20 | 0.48 |
| ▸ | EGFR | P00533 | 1/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | PFKFB3 | Q16875 | 1/20 | 0.47 |
| ▸ | PFKFB4 | Q16877 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 5/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | CASR | P41180 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1505244 | 0.82 | LOXL2 (0.48) | RAB9ANPC1ALDH1A1SMN1; SMN2AGTR1 | |
| SCHEMBL1505331 | 0.81 | USP5 (0.56) | RAB9ANPC1ALDH1A1SMN1; SMN2AGTR1 | |
| SCHEMBL1505506 | 0.81 | RAB9A (0.49) | RAB9ANPC1ALDH1A1SMN1; SMN2AGTR1 | |
| SCHEMBL135137 | 0.80 | CASR (0.54) | RAB9ANPC1ALDH1A1SMN1; SMN2HPGD | |
| SCHEMBL131563 | 0.80 | RAB9A (0.54) | RAB9ANPC1ALDH1A1SMN1; SMN2HPGD | |
| SCHEMBL8672958 | 0.78 | RAB9A (0.60) | RAB9ANPC1ALDH1A1SMN1; SMN2AGTR1 | |
| SCHEMBL134016 | 0.78 | EGFR (0.57) | RAB9ANPC1ALDH1A1SMN1; SMN2AGTR1 | |
| SCHEMBL18392373 | 0.76 | HSD17B10 (0.56) | RAB9ANPC1ALDH1A1SMN1; SMN2HPGD | |
| SCHEMBL19125260 | 0.76 | RAB9A (0.46) | RAB9ANPC1ALDH1A1SMN1; SMN2AGTR1 | |
| SCHEMBL4604254 | 0.75 | EGFR (0.54) | RAB9ANPC1ALDH1A1SMN1; SMN2AGTR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150274674-A1 | PYRAZOLE OR TRIAZOLE COMPOUNDS AND THEIR USE FOR THE MANUFACTURE OF A MEDICAMENT FOR TREATING SOMATIC MUTATION-RELATED DISEASES | PTC THERAPEUTICS, INC. (US) | 2015-10-01 | — | — | US | disclosed |
| US-9051342-B2 | Pyrazole or triazole compounds and their use for the manufacture of a medicament for treating somatic mutation related diseases | PTC THERAPEUTICS, INC. (US) | 2015-06-09 | — | — | US | disclosed |
| EP-2402323-A2 | Pyrazole or triazole compounds and their use for the manufacture of a medicament for treating somatic mutation-related diseases | PTC Therapeutics, Inc. (US) | 2012-01-04 | — | — | EP | disclosed |
| EP-2363129-A1 | Pyrazole or triazole compounds and their use for the manufacture of a medicament for treating somatic mutation-related diseases | PTC Therapeutics, Inc. (US) | 2011-09-07 | — | — | EP | disclosed |
| EP-2316452-A1 | Pyrrol derivatives, uses thereof | PTC Therapeutics, Inc. (US) | 2011-05-04 | — | — | EP | disclosed |
| US-20080280869-A1 | Pyrazole or Triazole Compounds and Their Use for the Manufacture of a Medicament for Treating Somatic Mutation-Related Diseases | PTC THERAPEUTICS, INC. | 2008-11-13 | — | — | US | disclosed |
| EP-1799207-A2 | PYRAZOLE OR TRIAZOLE COMPOUNDS AND THEIR USE FOR THE MANUFACTURE OF A MEDICAMENT FOR TREATING SOMATIC MUTATION-RELATED DISEASES | PTC Therapeutics, Inc. (US) | 2007-06-27 | — | — | EP | disclosed |
| WO-2006044502-A2 | PYRAZOLE OR TRIAZOLE COMPOUNDS AND THEIR USE FOR THE MANUFACTURE OF A MEDICAMENT FOR TREATING SOMATIC MUTATION-RELATED DISEASES | PTC THERAPEUTICS, INC. (US) | 2006-04-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080280869-A1 | Pyrazole or Triazole Compounds and Their Use for the Manufacture of a Medicament for Treating Somatic Mutation-Related Diseases | UPF1, RNMT, VHL | RAB9A 3615/4885NPC1 1560/4885ALDH1A1 2509/4885 |
| US-20150274674-A1 | PYRAZOLE OR TRIAZOLE COMPOUNDS AND THEIR USE FOR THE MANUFACTURE OF A MEDICAMENT FOR TREATING SOMATIC MUTATION-RELATED DISEASES | UPF1, RNMT, VHL | RAB9A 3615/4885NPC1 1560/4885ALDH1A1 2509/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.